Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service mechanical circulatory support cases in Connecticut: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (146 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 0 | 187 | 46% |
| 2020 | 0 | 188 | 50% |
| 2021 | 0 | 153 | 53% |
Percutaneous ventricular assist and intra-aortic balloon pump. Professional codes (what the surgeon bills): CPT 33990, 33991, 33995, 33967, 33970; the hospital bills MS-DRG 268, 269.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Connecticut; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 4 | 1,076−3%/yr | −3%/yr | 0.6 | 0% | 1,080 in 2030+0.1%/yr |
| Pennsylvania | 2 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Coronary intervention (PCI) | 40 | 1,475−9.6%/yr | −9.6%/yr | 3.60.7× | 0% | 1,300 in 2030−2.1%/yr |
| Structural heart (TAVR, TEER) |
Mechanical circulatory support in every state, and its device makers · Every procedure market in Connecticut · Every state · Compare with New York
| ≈ 40 |
| – |
| 2026 est. | ≈ 40 | – |
| 2022 | 1 | 171 | 54% |
| 2023 | 0 | 158 | 57% |
| 2024 | 1 | 152 | 59% |
| 2025 from claims | – | 43 35–50 | 63% |
| 2026 forecast | – | 45 35–56 | 62% |
| 2027 forecast | – | 45 33–59 | 63% |
| 2028 forecast | – | 45 32–62 | 64% |
| 2029 forecast | – | 45 30–64 | 65% |
| 2030 forecast | – | 45 29–66 | 65% |
In 2024, 100% inpatient hospital.
| 838−4.5%/yr |
| −4.5%/yr |
| 0.6 |
| 0% |
| 950 in 2030+2%/yr |
| Massachusetts | 3 | 596−1.7%/yr | −1.7%/yr | 0.6 | 0% | 560 in 2030−0.9%/yr |
| New Jersey | 1 | 507+0.1%/yr | +0.1%/yr | 0.5 | 0% | 870 in 2030+9.4%/yr |
| New Hampshire | 2 | 133+3.3%/yr | +3.3%/yr | 0.6 | 0% | 120 in 2030−1.2%/yr |
| 32 |
| 563−1.1%/yr |
| −1.1%/yr |
| 1.40.8× |
| 0% |
| 1,000 in 2030+10%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Enablecv leads with 85% of company spending on these surgeons in 2025, +85 pts on 2024.
In 2025, 2 companies reported engagement with Connecticut’s surgeons worth $698 in consulting, speaking, meals and travel tied to these products, about $698 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 48 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.